Literature DB >> 16098060

Normal and leukaemic stem cells.

Dominique Bonnet1.   

Abstract

The blood-related cancer leukaemias were the first diseases where human cancer stem cells, or leukaemic stem cells (LSC), were isolated. The haematopoietic system is one of the best tissues for investigating cancer stem cells, because the developmental hierarchy of normal blood formation is well defined. Leukaemias can now be viewed as aberrant haematopoietic processes initiated by rare LSC that have maintained or reacquired the capacity for indefinite proliferation through accumulated mutations and/or epigenetic changes. Yet, despite their critical importance, much remains to be learned about the developmental origin of LSC and the mechanisms responsible for their emergence in the course of the disease. This report will review our current knowledge on normal and LSC development and examine the impact of these discoveries may have clinically and in our understanding of the leukaemogenic process.

Entities:  

Mesh:

Year:  2005        PMID: 16098060     DOI: 10.1111/j.1365-2141.2005.05596.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.

Authors:  Simon B Zeichner; Martha L Arellano
Journal:  Curr Treat Options Oncol       Date:  2015-08

Review 2.  Tumour-associated antigens: considerations for their use in tumour immunotherapy.

Authors:  Adam J Linley; Murrium Ahmad; Robert C Rees
Journal:  Int J Hematol       Date:  2011-03-01       Impact factor: 2.490

3.  Characterization of chronic myeloid leukemia stem cells.

Authors:  Jonathan M Gerber; Lu Qin; Jeanne Kowalski; B Douglas Smith; Constance A Griffin; Milada S Vala; Michael I Collector; Brandy Perkins; Marianna Zahurak; William Matsui; Christopher D Gocke; Saul J Sharkis; Hyam I Levitsky; Richard J Jones
Journal:  Am J Hematol       Date:  2011-01       Impact factor: 10.047

Review 4.  Therapeutic implications of leukemic stem cell pathways.

Authors:  Saranya Chumsri; William Matsui; Angelika M Burger
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

5.  Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations.

Authors:  Jonathan M Gerber; Jessica L Gucwa; David Esopi; Meltem Gurel; Michael C Haffner; Milada Vala; William G Nelson; Richard J Jones; Srinivasan Yegnasubramanian
Journal:  Oncotarget       Date:  2013-05

6.  Persistence to anti-cancer treatments in the stationary to proliferating transition.

Authors:  Sivan Pearl Mizrahi; Orit Gefen; Itamar Simon; Nathalie Q Balaban
Journal:  Cell Cycle       Date:  2016-11-01       Impact factor: 4.534

Review 7.  Precision therapy for acute myeloid leukemia.

Authors:  Xue Yang; Jianxiang Wang
Journal:  J Hematol Oncol       Date:  2018-01-05       Impact factor: 17.388

8.  The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis.

Authors:  Claudia Scholl; Dimple Bansal; Konstanze Döhner; Karina Eiwen; Brian J P Huntly; Benjamin H Lee; Frank G Rücker; Richard F Schlenk; Lars Bullinger; Hartmut Döhner; D Gary Gilliland; Stefan Fröhling
Journal:  J Clin Invest       Date:  2007-03-08       Impact factor: 14.808

9.  Comparison of toxicity of benzene metabolite hydroquinone in hematopoietic stem cells derived from murine embryonic yolk sac and adult bone marrow.

Authors:  Jie Zhu; Hong Wang; Shuo Yang; Liqiao Guo; Zhen Li; Wei Wang; Suhan Wang; Wenting Huang; Liping Wang; Tan Yang; Qiang Ma; Yongyi Bi
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells.

Authors:  Yahui Ding; Huier Gao; Yu Zhang; Ye Li; Neil Vasdev; Yingdai Gao; Yue Chen; Quan Zhang
Journal:  J Hematol Oncol       Date:  2016-09-22       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.